Healing

TB-500 (Thymosin Beta-4 Acetate)

Tetradecapeptide · Actin-binding sequence · 43 amino acids

FDA · CATEGORY 2 (2023)

Half-life

~5 hours

Short

minsdays

Route

SubQ injection

Evidence

Clinical trial data

Risk

Standard

Overview

Known for

Systemic healing peptide. Promotes cell migration, new blood vessel formation, and reduces inflammation throughout the body. Aids in wound healing, muscle repair, flexibility, and hair regrowth.

Mechanism

Synthetic version of thymosin beta-4 — naturally occurring protein that promotes wound healing, cell migration, angiogenesis, and reduces inflammation.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
Natural / Topping UpNatural
FDA category
Category 2 (2023)

Evidence & standing

Evidence base
Clinical trial data
Risk level
Standard
Clinical phase
Phase 2
Best studies
7 references
  • Malinda et al. (1999) J Invest Dermatol 113(3):364-8 — Wound healing in rats (42-61% improvement)
  • Kleinman & Sosne (2016) Vitam Horm 102:251-75 — Dermal healing review (Phase 2 stasis/pressure ulcers)
  • Sosne et al. (2002) Exp Eye Res 74:293-9 — Corneal wound healing
  • Bock-Marquette et al. (2004) Nature 432:466-72 — Cardiac repair
  • ClinicalTrials.gov: NCT00832091 (venous stasis ulcers)
  • NOT FDA APPROVED
  • Phase 2 dermal/corneal trials showed accelerated healing by ~1 month

Dosage & protocol

Typical dose
750mcg
Research range
2–5 mg
Cycle
4 weeks on / 2 weeks off
Onset
10 days first effects
Full effect
42 days
Half-life
~4-6h
~4-6 hours (estimated)
Protocol

Loading: 750mcg-2mg twice weekly for 4-6 weeks. Maintenance: 500mcg-1mg weekly. SubQ.

Time to effects

EARLY: 1-2 weeks

FULL: 4-8 weeks

Week 1-2: Reduced inflammation, improved flexibility. Some report a 'loosening' of tight/scarred tissue.

Week 2-4: Systemic healing effects. Improved recovery between training sessions. Hair regrowth may begin in some individuals.

Week 4-8: Significant healing of chronic injuries. Flexibility improvements. Visible wound healing enhancement.

Loading phase (higher dose for first 4-6 weeks) is important — don't start at maintenance. Minimum commitment: 6 weeks.

Recommended vial
  • 5mg vials

Loading at 2mg/wk, 5mg = 2.5 weeks ✓. 10mg at loading = 5 weeks ✓. Maintenance (500mcg-1mg/wk): use 2mg vials.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Limited data: headache, lethargy, flu-like symptoms initially (reported). Malinda 1999 animal data: well-tolerated.

Interactions

Unknown — no drug interaction studies

Do not combine
BPC-157 10mg + TB-500 10mg (Blend)BPC-157 10mg + TB-500 10mg (Blend) BPC-157 5mg + TB-500 5mg (Blend)BPC-157 5mg + TB-500 5mg (Blend) GLOW Blend (BPC 10mg + TB 10mg + GHK-Cu 50mg)GLOW Blend (BPC 10mg + TB 10mg + GHK-Cu 50mg) KLOW Blend (BPC 10mg + TB 10mg + GHK-Cu 50mg + KPV 10mg)KLOW Blend (BPC 10mg + TB 10mg + GHK-Cu 50mg + KPV 10mg)

Handle with research caution

  • Same angiogenesis concern as BPC-157 — avoid if active cancer/tumour history

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
3–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.